Format

Send to

Choose Destination
Ann Intern Med. 2010 Feb 16;152(4):218-24. doi: 10.7326/0003-4819-152-4-201002160-00006.

Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study.

Author information

1
University Hospital, Saint-Etienne, France. herve.decousus@chu-st-etienne.fr

Abstract

BACKGROUND:

Superficial venous thrombosis (SVT) is perceived to have a benign prognosis.

OBJECTIVE:

To assess the prevalence of venous thromboembolism in patients with SVT and to determine the 3-month incidence of thromboembolic complications.

DESIGN:

National cross-sectional and prospective epidemiologic cohort study. (ClinicalTrials.gov registration number: NCT00818688)

SETTING:

French office- and hospital-based vascular medicine specialists.

PATIENTS:

844 consecutive patients with symptomatic SVT of the lower limbs that was at least 5 cm on compression ultrasonography.

MEASUREMENTS:

Incidence of venous thromboembolism and extension or recurrence of SVT in patients with isolated SVT at presentation.

RESULTS:

Among 844 patients with SVT at inclusion (median age, 65 years; 547 women), 210 (24.9%) also had deep venous thrombosis (DVT) or symptomatic pulmonary embolism. Among 600 patients without DVT or pulmonary embolism at inclusion who were eligible for 3-month follow-up, 58 (10.2%) developed thromboembolic complications at 3 months (pulmonary embolism, 3 [0.5%]; DVT, 15 [2.8%]; extension of SVT, 18 [3.3%]; and recurrence of SVT, 10 [1.9%]), despite 540 patients (90.5%) having received anticoagulants. Risk factors for complications at 3 months were male sex, history of DVT or pulmonary embolism, previous cancer, and absence of varicose veins.

LIMITATION:

The findings are from a specialist referral setting, and the study was terminated before the target patient population was reached because of slow recruitment.

CONCLUSION:

A substantial number of patients with SVT exhibit venous thromboembolism at presentation, and some that do not can develop this complication in the subsequent 3 months.

PRIMARY FUNDING SOURCE:

GlaxoSmithKline, sanofi-aventis, and the Ministère Francais de la Santé et des Sports (Programme Hospitalier de Recherche Clinique).

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center